Pharmaceutical Benefits Advisory Committee

Telephone: (02) 6289 7099
Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELETION OF PHARMACEUTICAL BENEFIT ITEMS
EFFECTIVE 1 January 2020

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the deletion of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item	**PBAC Advice**
Verteporfin	The sponsor has requested the deletion of Visudyne® from the PBS. The sponsor stated that the product will be transferred to them (from Novartis Pharmaceuticals), effective 1 November 2019. After this date, registered supply of the product will cease, as the small volumes of supply are not commercially viable. The product will remain available to the small patient population via unlicensed supply. The PBAC noted that aflibercept and ranibizumab are PBS-listed for the same indication (subfoveal choroidal neovascularisation (CNV) due to macular degeneration) and there were very few services of verteporfin in 2018-19. The PBAC had no objections to this deletion request.

John Paul
Director
Health Technology Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
29 November 2019